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ABSTRACT
Introduction: Gout is characterized by recur-
rent episodes of acute inflammation of joint
structures, called gout flares, and flares are
commonly treated with nonsteroidal anti-in-
flammatory drugs (NSAIDs). The objective of
the study was to evaluate risk factors associated
with acute kidney injury (AKI) attributed to
NSAIDs in a cohort of patients who were
exposed to NSAIDs to treat gout flares prior to
urate-lowering therapy.
Methods: Retrospective analysis of a nested
cohort of 983 gout patients in whom general
variables (age, gender, renal function, ethanol
intake, hypertension, hyperlipidemia, diabetes,
vascular events, diuretic use) and also variables
related to gout and severity of gout (serum urate
levels, number for flares per year, presence of
tophi, joint distribution, X-ray involvement,
previous urate-lowering therapy) were available
for analysis. Outcomes considered were loss of
renal function attributed to NSAID prescription
following the RIFLE classification for (risk,
injury, and failure) for acute renal events. Vari-
ables associated with increased risk in Kaplan–
Meier survival analysis were tested with
multivariable Cox survival analysis, using time
from onset of gout to the event as time exposed
to NSAIDs.
Results: Of 983 patients, 55 (5.6%) experienced
AKI; the number of flares in the year previous to
the renal event and polyarticular joint distribu-
tion were associated with higher risk of renal
events.Othervariablespreviouslydescribed inthe
literature, such as previous chronic renal disease,
use of diuretics, and presence of previous vascular
events, were also independently associated with
increased risk of AKI. Interestingly, patients who
had been previously prescribed allopurinol
showed a lower risk of acute renal events.
Conclusion: In addition to classic risk factors,
the number of flares and extensive joint distri-
bution were associated with higher risk for renal
injury in patients with gout, while previous
prescription of allopurinol was associated with
lower risk.
Keywords: Adverse events; Chronic gout;
Gout; Kidney; NSAID
INTRODUCTION
Gout is characterized by the development of
recurrent episodes of acute inflammation (flares)
of joint structures, commonly named as gout
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flares or gout attacks [1]. Flares in patients with
gout are most commonly treated with nons-
teroidal anti-inflammatory drugs (NSAIDs), and
the highest labeled doses are commonly recom-
mended [2]. Among the serious adverse events
associated with the use of NSAIDs [3], renal
ones—including acute kidney injury (AKI) and
permanent loss of renal function [4]—are not
uncommon, especially in patients at risk [5].
Variables specifically related to gout severity,
such as joint distribution, the number of epi-
sodes of inflammation, or presence of topha-
ceous deposition, may be associated with a
more frequent use of NSAIDs, and therefore to
NSAID-related adverse events. Unfortunately,
these variables are not available from databases
in former publications [6]. We investigated risk
factors for developing AKI in a large cohort of
patients with gout in whom gout-specific vari-
ables were available.
METHODS
This was a retrospective analysis of data from a
cohort of patients with gout who visited our uni-
versityhospital,which is responsible for treating a
populationofhalf amillion, fromSeptember1992
to September 2013. At entrance in the follow-up
cohort, general data, biometrics, renal function,
cardiovascular risk factors, and previous compli-
cations due to medications for gout were incor-
porated into the dataset along with specific data
related to gout. The dataset capture was approved
by the local ethics committee andwrittenconsent
provided by the patients.
Outcomes considered were the presence of a
physician-based diagnosis history of suspected
or confirmed AKI attributed to NSAIDs in the
clinical file of the patient by a physician. The
files of the patients with an entry in the dataset
related to AKI were reviewed to ascertain the
endpoints. For AKI, RIFLE classification was
used, and at least a 25% decrease in estimated
clearance of creatinine with MDRD formula was
needed to fulfill criteria for risk, 50% for injury,
and 75% for failure [7].
Exploratory variables included age, gender,
body mass index (BMI), clinically significant
chronic kidney disease (CKD, defined as
glomerular filtration rate \60 ml/min), use of
diuretics, diabetes, hypertension, hyperlipi-
demia, previous vascular events, and previous
renal lithiasis. Gout-specific variables included
were time from onset of gout, number of joints
ever involved during the natural course of the
disease (monoarticular, oligoarticular, or pol-
yarticular gout), presence of X-ray abnormali-
ties related to gout, presence of subcutaneous
tophi, previous urate-lowering treatment (ULT),
number of episodes of acute inflammation
(flares) of gout in the year previous to consul-
tation, and serum urate at baseline.
Continuous variables are expressed as
mean± SD. Time from onset of gout was consid-
ered as time exposed to NSAIDs for analysis.
Kaplan–Meier estimates of survival using a
log-rank test were used to initially identify those
variables associated with the outcome (AKI).
Variables found to have a possible statistical
association (p\0.20) with AKI in the bivariable
analysis (p\0.20) were selected for amultivariate
Coxproportional hazard regressionanalysis using
a stepwisemodel, so that the variable showing the
highestnon-significantp statistic at every stepwas
withdrawn from the multivariate model until all
remaining variables showed statistical signifi-
cance (p\0.05). Hazard ratios (HR) and 95%
confidence intervals (95%CI)were obtained from
bivariable and multivariate models.
The robustness of the models was checked
with partial residuals plots to support the
hypothesis of proportional hazards. For
numerical variables, the proportional risk
hypothesis was tested categorizing variables
into quartiles. Statistical analyses were run in
the statistical package SPSS v19.0.
The cohort recruitment and follow-up were
approved by the Ethics and Investigation Board
at Cruces University Hospital and written con-
sent provided by the patients. This study did
not include any new intervention.
RESULTS
Twenty-one patients were excluded because
their flares had always been treated with col-
chicine or corticosteroids and they were never
exposed to NSAIDs for gout flares. A total of 983
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patients were included for analysis and for 774
(78.6%) of these the diagnosis was based on
urate crystal observation in synovial fluid or
samples aspirated from tophi. Three cases with
prerenal kidney injury related to gastrointesti-
nal bleeding were not adjudicated as AKI.
Time from onset of gout was 6.8 ± 7.1 years
(median 4; interquartile range 2–10), exposure
to NSAIDs being 6684 patients/year. General
characteristics of the patients are shown in
Table 1. A total of 39% (385/983) of the patients
had been on urate-lowering drugs, all but one of
them with allopurinol (43% on \300 mg/day,
57% on C300 mg/day).
The following AKI events occurred: risk of
renal dysfunction, 31 (3.15%); injury to the
kidney, 13 (1.32%); failure of kidney function,
11 (1.12%), with a total of 55 events (5.6%
cumulative incidence), 0.82 events per 100 pa-
tient-year exposure.
Variables independently associated with
increased risk of AKI in Kaplan–Meier, log-rank
bivariable survival analysis were age, gender,
hypertension, diabetes, previous CKD, previous
lithiasis, diuretic use, number of flares, pol-
yarticular distribution of joint involvement,
and previous vascular event. Cox regression
multivariate analysis showed that CKD, diuretic
use, previous vascular event, polyarticular dis-
tribution, number of episodes of inflammation
in the previous year, and absence of concomi-
tant ULT were independently associated with
increased risk (Table 2).
Overall, the concomitant use of allopurinol
was associatedwith a reduction in the risk of AKI.
An analysis to evaluate whether the reduction of
risk was associated with prescribed doses of
allopurinol did not reach statistical significance,
as all patients had been prescribed doses equal to
or lower than 300 mg/day (data not shown).








Age (years) 60.1 ± 13.1 59.7 ± 13.1 68.2 ± 12.1 \0.001
BMI (kg/m2) 27.9 ± 3.9 27.9 ± 3.9 27.6 ± 4.0 0.562
Time from onset (years) 6.8 ± 7.1 6.8 ± 7.1 7.9 ± 7.4 0.266
Serum urate (mg/dl) 8.98 ± 1.41 8.96 ± 1.39 9.38 ± 1.70 0.065
Flares (previous years) 3.6 ± 3.8 3.5 ± 3.6 5.5 ± 5.6 0.012
GFR (ml/min/1.73 m2) 88 ± 54 90 ± 54 57 ± 38 \0.001
Male/female 913/70 862/66 50/5 0.582
Hypertension (%) 46.8 45.6 74.5 \0.001
Diuretics (%) 27.3 24.3 56.4 \0.001
CKD stage\2 (%) 23.6 21.6 56.5 \0.001
Renal lithiasis (%) 9.2 9.7 0 0.034
Diabetes (%) 20.0 19.4 30.9 0.035
Hyperlipidemia (%) 45.2 45.4 41.2 0.634
Previous vascular event (%) 29.7 27.8 61.8 \0.001
Polyarticular 35.7 34.3 65.9 \0.001
Tophi 32.4 31.5 49.1 0.007
Concomitant allopurinol 39.8 39.4 25.4 0.155
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DISCUSSION
Although gout is a well-known disease, a
minority of patients receive adequate advice
and treatment [8]. Even a majority of patients
with long-standing gout do not receive ULT [9],
and half of those who receive them do not reach
therapeutic plasma urate levels even when
treated [10]. Although proper treatment of
hyperuricemia to target therapeutic serum urate
levels is associated with a decrease in the num-
ber of flares [11], persistence of hyperuricemia is
associated with an increase in the number and
severity of flares [12]. So far, the long-term
control of hyperuricemia and the subsequent
avoidance of NSAIDs have been associated with
improvement in renal function, the highest
impact observed in patients with CKD [13]. In
addition, treatment of hyperuricemia of gout
may be considered cost-effective in patients at
high risk of developing adverse events due to
the use of NSAIDs [14].
The number of flares and the presence of
polyarticular joint distribution were associated
with higher risk of AKI complications in our
patients. The number of flares and polyarticular
distribution could be considered as surrogates of
the use of NSAIDs, commonly prescribed at
high dose for gout flares. The clinical
implications for such findings are that recur-
rence of flares should be avoided by correct
implementation of ULT in patients with gout
[15, 16], prescribing adequate prophylaxis to
patients starting ULT [17], and a slow step-up
dosing of urate-lowering drugs should be con-
sidered [14] to minimize the risk of flares in
patients with renal function impairment.
The use of diuretics, previous vascular
events, and no previous treatment with
urate-lowering drugs were associated with risk
of developing AKI. Cyclooxygenase inhibition
causes marked impairment of renal function in
elderly patients, especially if treated with
diuretics or ACE inhibitors [18]. The rate of
adverse events caused by NSAIDs that required
hospitalization is increased in patients on ACE
inhibitors or diuretics, additional comorbidities
highly influencing the risk [5]. Although
short-term use of NSAIDs seems not to have a
clinically relevant impact on renal function in
patients with previous normal renal function
[19], even if administered at high doses [20], the
presence of CKD is considered a risk factor for
renal injury due to NSAIDs [21], and it has been
found to be associated with AKI in patients with
gout [6].
Interestingly, patients who had concomitant
allopurinol prescription were at lower risk of
Table 2 Risk ratios (95% conﬁdence interval limits) for variables included in Cox survival analysis
AKI, uncorrected AKI, corrected p
Diabetes 1.127 (0.611–2.078) 0.996 (0.541–1.831) 0.996
Age (years) 1.003 (0.977–1.030) 1.002 (0.976–1.029) 0.876
Gender (male) 0.551 (0.190–1.601) 0.593 (0.205–1.761) 0.335
Hypertension 1.396 (0.621–3.141) 1.448 (0.663–3.163) 0.353
Diuretic use 1.963 (0.988–3.898) 2.168 (1.130–4.161) 0.020
CKD stage\2 2.755 (1.435–5.286) 2.695 (1.404–5.172) 0.003
Previous vascular event 2.173 (1.708–4.383) 2.453 (1.259–4.782) 0.008
Polyarticular 3.560 (1.233–10.282) 3.90 (1.358–11.216) 0.011
Flares ([2 per year) 2.489 (1.194–5.187) 2.723 (1.030–5.693) 0.008
Not on allopurinol 3.634 (1.880–7.022) 3.921 (2.056–7.476) 0.000
Statistically signiﬁcant variables after correction are shown in bold
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developing AKI than patients not treated. The
impact of allopurinol treatment on renal func-
tion is debated, but some trials have shown
treatment with allopurinol to have a beneficial
effect on endothelial function and glomerular
filtration [22] even regardless of the impact on
serum urate levels [23]. Although not labelled in
most countries for such an indication, early
treatment of hyperuricemia in patients with
CKD is suggested by some authors [16].
The strength of this study lies in the avail-
ability of variables associated with the severity
of gout involvement such as the number of
flares, which may be a surrogate for the number
of times high-dose NSAIDs are used, and clinical
variables of chronicity of gout such as pol-
yarticular joint distribution and tophaceous
deposition, which may reflect a more frequent
use of low-dose NSAIDs or analgesics apart from
the flares. Limitations to the results include that
some variables known to be risk factors for AKI,
such as ACE inhibitors [18], were not included
in the protocol of the cohort. Also, the variable
for previous vascular event was heterogeneous,
as it included patients with acute and chronic
heart failure, stroke or myocardial infarction,
the presence of previous chronic heart failure
being the most likely cause associated with AKI
[21], but no further data were available for
analysis. The incidence of AKI may also have
been underestimated, as data regarding renal
function after flares was not always available
and therefore capture of adverse events was
missed. The highest doses of allopurinol were
not associated with a reduction of the risk of
AKI, but the number of patients was relatively
small and no data on the impact of allopurinol
treatment on serum urate levels was incorpo-
rated, as most patients did not have previous
controls, as reported previously in other studies
[9].
CONCLUSIONS
Along with known risk factors for renal adverse
events—such as CKD, previous vascular event,
and diuretic use—variables related to gout
severity, such as the number of acute episodes
of inflammation and polyarticular distribution,
were associated with such adverse events. Con-
comitant use of allopurinol was associated with
a reduction of the risk, but we cannot establish a
relationship with doses or serum urate levels
because of the lack of sufficient numbers of
patients and data. Appropriate treatment of
hyperuricemia of gout should be implemented
in any patient with a certain diagnosis of gout,
but especially in patients with comorbidities
and higher risk of developing adverse events to
NSAIDs.
ACKNOWLEDGEMENTS
This work was partially supported by a grant
from Asociacio´n de Reumato´logos del Hospital
de Cruces. No funding was received for article
processing charges. All named authors meet
the International Committee of Medical
Journal Editors (ICMJE) criteria for authorship
for this manuscript, take responsibility for the
integrity of the work as a whole, and have
given final approval for the version to be
published. Fernando Perez-Ruiz, as corre-
sponding author, warrants that this is an
original work, has not been published, except
in abstract form for congress presentation,
and is not being considered for publication in
any other journal. I take full responsibility for
the content of the work and guarantee that
the results are a true reflection of the facts to
the best of my knowledge. F. Perez-Ruiz
designed the study, collected data, made sta-
tistical analysis, and wrote the manuscript. No
external assistance has been received.
Disclosures. Fernando Perez-Ruiz: speaker/
consultant/advisory boards/educational activi-
ties for Ardea Biosciences, Menarini, Metabolex,
Novartis, Pfizer, and Savient.
Compliance with Ethics Guidelines. The
cohort recruitment and follow-up were
approved by the Ethics and Investigation Board
at Cruces University Hospital and written con-
sent provided by the patients. This study did
not include any new intervention.
Rheumatol Ther (2017) 4:419–425 423
Data Availability. The datasets generated
and/or analyzed during the current study are
available from the corresponding author on
reasonable request.
Open Access. This article is distributed
under the terms of the Creative Commons
Attribution-NonCommercial 4.0 International
License (http://creativecommons.org/licenses/
by-nc/4.0/), which permits any noncommer-
cial use, distribution, and reproduction in any
medium, provided you give appropriate credit
to the original author(s) and the source, provide
a link to the Creative Commons license, and
indicate if changes were made.
REFERENCES
1. Richette P, Bardin T. Gout. Lancet.
2010;375(9711):318–28.
2. Zhang W, Doherty M, Pascual E, et al. EULAR evi-
dence based recommendations for gout Part II.
Management. Report of a task force of the EULAR
Standing Committee for International Clinical
Studies Including Therapeutics (ESCISIT). Ann
Rheum Dis. 2006;65:1312–24.
3. Wolfe MM, Licchtesntein DR, Singh G. Gastroin-
testinal toxicity of nonsteroidal antiinflammatory
drugs. N Engl J Med. 1999;340(24):1888–99.
4. Huerta C, Castellsague J, VAras-Lorenzo C, Gar-
cia-Rodriguez LA. Nonsteroidal anti-inflammatory
drugs and the risk of ARF in the general population.
Am J Kidney Dis. 2005;45(3):531–9.
5. Pratt N, Roughead EE, Ryan P, Gilbert AL. Different
impact of NSAIDs on rate of adverse events that
require hospitalization in high-risk and general
veteran populations. Drugs Aging.
2010;27(1):63–71.
6. Moon KW, Kim J, Kim JH, et al. Risk factors for
acute kidney injury by non-steroidal anti-inflam-
matory drugs in patients with hyperuricaemia.
Rheumatol (Oxford). 2011. doi:10.1093/
rheumatology/ker286.
7. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky
P, The ADQI Workgroup. Acute renal failure—defi-
nition, outcome measures, animal models, fluid
therapy and information technology needs: the
Second International Consensus Conference of the
Acute Dialysis Quality Initiative (ADQI) Group.
Criti Care. 2004;8:204–12.
8. Doherty M, Jansen TL, Nuki G, et al. Gout: why is
this ‘‘curable’’ disease so seldom cured? Ann Rheum
Dis. 2012. doi:10.1136/annrheumdis-2012-201687.
9. Annemans L, Spaepen E, Gaskin M, et al. Gout in
the UK and Germany: prevalence, comorbidities
and management in general practice 2000–2005.
Ann Rheum Dis. 2007;67:960–6.
10. Perez-Ruiz F, Carmona L, Yebenes MJ, et al. An
audit of the variability of diagnosis and manage-
ment of gout in the rheumatology setting: the gout
evaluation and management study. J Clin
Rheumatol. 2011;17(7):349–55.
11. Perez-Ruiz F, Liote´ F. Lowering serum uric acid
levels: what is the optimal target for improving
clinical outcomes in gout? Arthritis Rheum.
2007;57(7):1324–8.
12. Gutman AB. The past four decades of progress in
the knowledge of gout, with an assessment of the
present status. Arthritis Rheum. 1973;16(4):431–45.
13. Perez-Ruiz F, Calabozo M, Herrero-Beites AM, Gar-
cia-Erauskin G, Pijoan JI. Improvement of renal
function in patients with chronic gout after proper
control of hyperuricemia and gouty bouts.
Nephron. 2000;86:287–91.
14. Bosi-Ferraz M, O’Brien B. A cost effectiveness anal-
ysis of urate lowering drugs in nontophaceous
recurrent gouty arthritis. J Rheumatol.
1995;22:908–14.
15. Khanna PP, Perez-Ruiz F, Maranian P, Khanna D.
Long-term therapy for chronic gout results in clin-
ically important improvements in the health-re-
lated quality of life: short form-36 is responsive to
change in chronic gout. Rheumatol (Oxford).
2011;50(4):740–5.
16. Khanna D, FitzGerald JD, Khanna PP, et al. 2012
American College of Rheumatology guidelines for
management of gout. Part I: systematic non-phar-
macologic and pharmacologic therapeutic approa-
ches to hyperuricemia. Arthitis Rheum (Hoboken).
2012;64(10):1431–46.
17. Wortmann RL, MacDonald PA, Hunt B, Jackson RL.
Effect of prophylaxis on gout flares after the initia-
tion of urate-lowering therapy: analysis of data
from three phase III trials. Clin Ther.
2011;32(14):2386–97.
18. Juhlin T, Bjo¨rkman S, Ho¨glund P. Cyclooxygenase
inhibition causes marked impairment of renal
function in elderly subjects treated with diuretics
424 Rheumatol Ther (2017) 4:419–425
and ACE-inhibitors. Eur J Heart Fail.
2005;7:1049–56.
19. Nygard P, Jansman FG, Kruik-Kolloffel WJ, Barnaart
AF, Brouwers JR. Effects of short-term addition of
NSAID to diuretics and/or RAAS-inhibitors on blood
pressure and renal function. Int J Clin Pharm.
2012;34(3):468–74.
20. Schumacher HR, Berger MF, Li-Yu J, Perez-Ruiz F,
Burgos-Vargas R, Li C. Efficacy and tolerability of
celecoxib in the treatment of acute gouty arthritis: a
randomized controlled trial. J Rheumatol.
2012;39(9):1859–66.
21. Musu M, Finco G, Antonucci R, et al. Acute
nephrotoxicity of NSAID from the foetus to the
adult. Eur Rev med Pharmacol Sci.
2011;15(12):1461–72.
22. Kanbay M, Huddam B, Azak A, et al. A randomized
study of allopurinol on endothelial function and
estimated glomular filtration rate in asymptomatic
hyperuricemic subjects with normal renal function.
Clin J Am Soc Nephrol. 2011;6(8):1887–94.
23. Melendez-Ramirez G, Perez-Mendez O, Lopez-Oso-
rio C, Kuri-Alfaro J, Espinola-Zavaleta N. Effect of
the treatment with allopurinol on the endothelial
function in patients with hyperuricemia. Endocr
Res. 2012;37(1):1–6.
Rheumatol Ther (2017) 4:419–425 425
